Home/Investors/Fidelity Management & Research Company

Fidelity Management & Research Company

Biotech Investor · 8 portfolio companies

Portfolio

8

Combined Value

$250.5M

Focus Areas

18

Top Stage

phase-1

Investment Focus

Rare Genetic Diseases Neuromuscular Hematology Rare Disease Genetics & Genomics Oncology Immunology Rare Diseases Infectious Diseases Central Nervous System Huntington's Disease Genetic Disorders Hematologic Malignancies Autoimmune Diseases Metabolic Disorders

Portfolio Companies

Company	Stage	Valuation	Focus
Fulcrum Therapeutics	Phase 3	$250.5M	Rare Genetic Diseases, Neuromuscular
NewBiologix	phase-1	—	Rare Disease, Genetics & Genomics
Syngene International	platform	—	Oncology, Immunology
ElevateBio	Pre-clinical	—	Huntington's Disease, Genetic Disorders
Wugen	Phase 2	—	Oncology, Hematologic Malignancies
Homology Medicines	Phase 2	—	Rare Genetic Diseases, Metabolic Disorders
Odyssey Therapeutics	phase-1	—	Oncology, Immunology
ReNAgade Therapeutics	preclinical	—	Genetic Diseases, Neurology

Frequent Co-Investors

Atlas Venture2 shared ARCH Venture Partners2 shared OrbiMed1 shared GV1 shared Deerfield Management1 shared MPM Capital1 shared Redmile Group1 shared ICICI Prudential Asset Management1 shared